CymaBay Therapeutics to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced a conference call scheduled for May 13, 2021, to discuss its Q1 2021 financial results and provide a business update. The call will take place at 4:30 p.m. Eastern Time, and interested parties can join by calling 877-407-0784 (U.S.) or 201-689-8560 (international), with Conference ID #13718350. The live audio webcast will be accessible on the company's Investor Relations website.

Positive

• The company is conducting a global, Phase 3 registration study of seladelpar for primary biliary cholangitis (PBC).
• Seladelpar has received orphan designation and Breakthrough Therapy Designation from the FDA, indicating strong regulatory support.

Negative

• None.

NEWARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, May 13, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2021 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13718350. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. CymaBay is currently conducting a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, phase 3 study to evaluate the safety and efficacy of seladelpar (RESPONSE) in patients with PBC. For more information about RESPONSE, please visit: www.pbcstudies.com.

For additional information about CymaBay visit www.cymabay.com.

Public Relations Contact:

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

FAQ

When will CymaBay announce its financial results for Q1 2021?

CymaBay will announce its Q1 2021 financial results on May 13, 2021.

What is the significance of the Phase 3 study for seladelpar?

The Phase 3 study aims to evaluate the safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC), which is crucial for potential market approval.

How can investors access the conference call by CymaBay?

Investors can access the conference call by dialing 877-407-0784 from the U.S. or 201-689-8560 internationally, using Conference ID #13718350.

What designations has seladelpar received from regulatory agencies?

Seladelpar has received orphan designation from the FDA and EMA, and Breakthrough Therapy Designation from the FDA.